Horizon Technology Finance Strengthens Life Sciences Team With Two New Senior-Level Hires
December 20 2016 - 4:15PM
Horizon Technology Finance Corporation (NASDAQ:HRZN) (“Horizon”), a
leading specialty finance company that provides capital in the form
of secured loans to venture capital backed companies in the
technology, life science, healthcare information and services, and
cleantech industries, announced today that its Advisor, Horizon
Technology Finance Management LLC, has expanded its life sciences
team with the appointments of Mishone Donelson as Managing Director
and Lillian Mu as Portfolio Manager.
Gerald A. Michaud, President, commented, “We are
very excited to have Mishone and Lillian join our life sciences
team. They both bring a wealth of expertise and solid industry
relationships to Horizon’s life sciences platform, broadening and
strengthening our existing capabilities. We look forward to their
contributions as we focus on expanding our investments in the life
sciences market.”
Mr. Donelson has over 15 years of investment and
business development experience. Previously, he was a Principal at
Fairview Capital Partners, where he led investment and business
development efforts for Fairview’s venture capital, private equity
and direct co-investment portfolios, including healthcare and life
sciences opportunities. Prior to that, he served at Ariel
Investments as an equity research analyst and as Chief of Staff to
the Chairman and CEO. Formerly, Mr. Donelson served as a consultant
for Accenture. He also helped launch the Memphis Academy of Science
and Engineering, Tennessee’s first charter school. Mishone holds a
Bachelor of Science in Chemical Engineering from MIT and a Master
of Business Administration from the Kellogg School of Management,
where he was a Robert Toigo Fellow.
Before joining Horizon, Ms. Mu was a Senior
Investment Associate at Connecticut Innovations, where she sourced,
evaluated and structured new investment opportunities in life
sciences, including conducting due diligence, and managed portfolio
companies. She served as a board observer for numerous life science
companies, including Arvinas, Aeromics, Bioarry, Tangen, Thetis and
AxioMx (ABC:LN). Prior to joining Connecticut Innovations, Ms. Mu
spent more than 15 years in research and development in academia
and the pharmaceutical industry, including positions at the
University of Pennsylvania, GlaxoSmithKline, Merck and Pfizer. She
also has extensive experience in international public health,
having spent six months in Zambia as Pfizer’s Global Health Fellow.
Ms. Mu has authored or coauthored more than 30 articles and
chapters in peer-reviewed scientific journals. Lillian holds a
Bachelor of Science in Biology from Arcadia University, a Master of
Science in Biological Sciences from Drexel University and a Master
of Business Administration from the University of New Haven.
About Horizon Technology
FinanceHorizon Technology Finance Corporation is a leading
specialty finance company that provides capital in the form of
secured loans to venture capital backed companies in the
technology, life science, healthcare information and services, and
cleantech industries. The investment objective of Horizon is to
maximize its investment portfolio’s return by generating current
income from the debt investments it makes and capital appreciation
from the warrants it receives when making such debt investments.
Headquartered in Farmington, Connecticut, Horizon has regional
offices in Walnut Creek, California and Reston, Virginia. Horizon's
common stock trades on the NASDAQ Global Select Market under the
ticker symbol "HRZN". To learn more, please visit
www.horizontechfinance.com.
Forward-Looking
StatementsStatements included herein may constitute
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Statements other than
statements of historical facts included in this press release may
constitute forward-looking statements and are not guarantees of
future performance, condition or results and involve a number of
risks and uncertainties. Actual results may differ materially from
those in the forward-looking statements as a result of a number of
factors, including those described from time to time in our filings
with the Securities and Exchange Commission. Horizon undertakes no
duty to update any forward-looking statement made herein. All
forward-looking statements speak only as of the date of this press
release.
Contacts:
Horizon Technology Finance
Daniel R. Trolio
Vice President of Finance and
Interim Chief Financial Officer
(860) 674-9977
dtrolio@horizontechfinance.com
Investor Relations and Media Contacts:
The IGB Group
Scott Eckstein / Leon Berman
(212) 477-8261 / (212) 477-8438
seckstein@igbir.com / lberman@igbir.com
Horizon Technology Finance (NASDAQ:HRZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Horizon Technology Finance (NASDAQ:HRZN)
Historical Stock Chart
From Apr 2023 to Apr 2024